

Trihydroxycholestanoic Acid

Chemical Properties


CAS No. : 547-98-8

Formula: C₂₇H₄₆O₅

Molecular Weight: 450.66

Appearance:

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	Trihydroxycholestanoic acid is an intermediate in the biosynthesis of cholic acid .1 Elevated plasma levels of trihydroxycholestanoic acid have been found in patients with Zellweger syndrome, a neurological disorder characterized by mutations in PEX genes which result in defects in peroxisome formation.2,3
Targets(IC50)	Others

Solubility Information

Solubility	Chloroform: Slightly soluble,Heating is recommended. Ethanol: Slightly soluble DMSO: Slightly soluble (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.219 mL	11.0948 mL	22.1897 mL
5 mM	0.4438 mL	2.219 mL	4.4379 mL
10 mM	0.2219 mL	1.1095 mL	2.219 mL
50 mM	0.0444 mL	0.2219 mL	0.4438 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

- Keane, M.H., Overmars, H., Wikander, T.M., et al. Bile acid treatment alters hepatic disease and bile acid transport in peroxisome-deficient PEX2 Zellweger mice. *Hepatology* 45(4), 982-997 (2007).
- Ferdinandusse, S., Overmars, H., Denis, S., et al. Plasma analysis of di- and trihydroxycholestanoic acid diastereoisomers in peroxisomal α -methylacyl-CoA racemase deficiency. *J. Lipid Res.* 42(1), 137-141 (2001).
- Klouwer, F.C.C., Berendse, K., Ferdinandusse, S., et al. Zellweger spectrum disorders: Clinical overview and management approach. *Orphanet J. Rare Dis.* 10, 151 (2015).

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481